Pictet Asset Management SA Boosts Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Pictet Asset Management SA boosted its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) by 10.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,243 shares of the company’s stock after buying an additional 4,493 shares during the quarter. Pictet Asset Management SA’s holdings in Vir Biotechnology were worth $1,254,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its stake in Vir Biotechnology by 127.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $25,000 after acquiring an additional 560 shares during the period. US Bancorp DE lifted its stake in Vir Biotechnology by 175.1% in the second quarter. US Bancorp DE now owns 982 shares of the company’s stock worth $25,000 after acquiring an additional 625 shares during the period. SeaCrest Wealth Management LLC purchased a new stake in Vir Biotechnology in the second quarter worth about $36,000. Banque Cantonale Vaudoise purchased a new stake in Vir Biotechnology in the second quarter worth about $63,000. Finally, Quantbot Technologies LP purchased a new stake in Vir Biotechnology in the first quarter worth about $64,000. 64.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

VIR has been the subject of a number of research reports. Barclays lowered their price objective on shares of Vir Biotechnology to $67.00 in a research note on Monday, August 15th. TheStreet upgraded shares of Vir Biotechnology from a “d” rating to a “c-” rating in a report on Monday, October 10th. Needham & Company LLC reduced their target price on shares of Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating for the company in a report on Friday, November 4th. SVB Leerink boosted their target price on shares of Vir Biotechnology from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Friday, November 4th. Finally, Morgan Stanley boosted their target price on shares of Vir Biotechnology from $15.00 to $18.00 and gave the stock an “underweight” rating in a report on Friday, November 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $52.50.

Insider Activity at Vir Biotechnology

In related news, major shareholder Endurance (Cayman) Ltd Svf sold 132,978 shares of the firm’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $27.22, for a total transaction of $3,619,661.16. Following the completion of the sale, the insider now directly owns 21,953,302 shares of the company’s stock, valued at approximately $597,568,880.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Endurance (Cayman) Ltd Svf sold 132,978 shares of the firm’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $27.22, for a total transaction of $3,619,661.16. Following the completion of the transaction, the insider now directly owns 21,953,302 shares in the company, valued at approximately $597,568,880.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 17,915 shares of the firm’s stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $20.67, for a total value of $370,303.05. Following the transaction, the director now owns 1,416,919 shares of the company’s stock, valued at $29,287,715.73. The disclosure for this sale can be found here. In the last ninety days, insiders sold 262,875 shares of company stock valued at $6,954,888. 22.40% of the stock is owned by insiders.

Vir Biotechnology Stock Up 2.7 %

VIR opened at $27.41 on Wednesday. The firm’s 50-day moving average price is $22.18 and its 200-day moving average price is $24.48. Vir Biotechnology, Inc. has a 52-week low of $18.05 and a 52-week high of $58.00. The company has a market cap of $3.65 billion, a P/E ratio of 3.23 and a beta of -0.01.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Stories

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.